Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.
Cell Metab
; 33(3): 479-498, 2021 03 02.
Article
in English
| MEDLINE | ID: covidwho-1039321
ABSTRACT
The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology. Here, I update concepts informing how metabolic disorders and their co-morbidities modify the susceptibility to, natural history, and potential treatment of SARS-CoV-2 infection, with a focus on human biology. New data informing genetic predisposition, epidemiology, immune responses, disease severity, and therapy of COVID-19 in people with obesity and diabetes are highlighted. The emerging relationships of metabolic disorders to viral-induced immune responses and viral persistence, and the putative importance of adipose and islet ACE2 expression, glycemic control, cholesterol metabolism, and glucose- and lipid-lowering drugs is reviewed, with attention to controversies and unresolved questions. Rapid progress in these areas informs our growing understanding of SARS-CoV-2 infection in people with diabetes and obesity, while refining the therapeutic strategies and research priorities in this vulnerable population.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Mellitus
/
Heart Disease Risk Factors
/
COVID-19
/
Metabolic Diseases
/
Obesity
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cell Metab
Journal subject:
Metabolism
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS